AJCN Cancer Health Disparities Conference
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keane, W. F.
Right arrow Articles by O'Donnell, M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keane, W. F.
Right arrow Articles by O'Donnell, M. P.
Agricola
Right arrow Articles by Keane, W. F.
Right arrow Articles by O'Donnell, M. P.

American Journal of Clinical Nutrition, Vol 47, 157-160, Copyright © 1988 by The American Society for Clinical Nutrition, Inc

REVIEW ARTICLES

Hyperlipidemia and the progression of renal disease

WF Keane, BL Kasiske and MP O'Donnell
Department of Medicine, University of Minnesota Medical School, Minneapolis 55415.

Focal glomerulosclerosis (FGS) is commonly seen in human and in experimental models of chronic renal disease. Although considerable experimental data suggest that hypertension is important in progressive nephron damage, recent studies also have indicated that abnormal lipid metabolism may be an independent risk factor in the pathogenesis of FGS. Indeed, the synergistic impact of hypertension and hyperlipidemia in the pathogenesis of FGS may be analogous to the role of these factors in the pathogenesis of atherosclerosis. This review focuses on some of the recent and pertinent data that support a role of lipid- mediated glomerular injury in the pathogenesis of progressive renal disease.


This article has been cited by other articles:


Home page
 CJASNHome page
C. Musso, E. Javor, E. Cochran, J. E Balow, and P. Gorden
Spectrum of Renal Diseases Associated with Extreme Forms of Insulin Resistance
Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 616 - 622.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
A. R. Chade, A. Lerman, and L. O. Lerman
Kidney in Early Atherosclerosis
Hypertension, June 1, 2005; 45(6): 1042 - 1049.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
V G Athyros, D P Mikhailidis, A A Papageorgiou, A N Symeonidis, A N Pehlivanidis, V I Bouloukos, and M Elisaf
The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study
J. Clin. Pathol., July 1, 2004; 57(7): 728 - 734.
[Abstract] [Full Text] [PDF]

Home page
 ANGIOLOGYHome page
M. Elisaf and D. P. Mikhailidis
Statins and Renal Function
Angiology, September 1, 2002; 53(5): 493 - 502.
[Abstract] [PDF]

Home page
 CLIN PEDIATRHome page
J. D. Hanna, J. W. Foreman, and J. C.M. Chan
Chronic Renal Insufficiency in Infants and Children
Clinical Pediatrics, June 1, 1991; 30(6): 365 - 384.
[PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by The American Society for Nutrition